TICKERNERD
Menu
INDVINDVHealthcare · Drug Manufacturers - Specialty & Generic

INDV Stock Forecast: Indivior Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$35
−0.60% on the day

The 4 Wall Street analysts covering Indivior Pharmaceuticals, Inc. hold a median 12-month price target of $50 — +43.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 2 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.1B
Ticker Nerd rank
97 / 100
Median analyst target
$50
Analysts covering
4
Revenue$343.0M+13.6% y/y
Operating income$159.0M
Net income$122.0M
Free cash flow$222.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
−6.8%
YTD
−2.9%
1Y
+41.2%
From 52W high
−16.7%
From 52W low
+54.8%
$23
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INDV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Indivior Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Revisions
97
Value
96
Volatility
92
Growth
84
Momentum
82
Issuance
54
Size
26
Accruals
26

Quality (98): The business earns solid, repeatable profits on what it owns.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INDV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INDV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40$45$50$55Oct 25Jan 26Apr 26Jul 26INDVHigh $53Median $50Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $43Median $50High $53

The green dot is the last close — the median target sits +43.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026BarclaysMaintainsOverweight$46 → $43
18 June 2026BarclaysInitiatesOverweight$46
18 June 2026BarclaysInitiatesOverweight—
12 Jan 2026HC Wainwright & Co.MaintainsBuy—
31 Oct 2025Piper SandlerReiteratesOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 Aug 2025Craig-HallumMaintainsBuy—
6 Aug 2025HC Wainwright & Co.InitiatesBuy—
22 July 2025JefferiesAssumesBuy$20
30 June 2025Craig-HallumMaintainsBuy—
6 Mar 2025Piper SandlerMaintainsOverweight—
25 Oct 2024Piper SandlerReiteratesOverweight—
11 Oct 2024Craig-HallumMaintainsBuy—
11 Oct 2024Piper SandlerReiteratesOverweight—
13 Sept 2024Piper SandlerReiteratesOverweight—
23 July 2024Piper SandlerInitiatesOverweight—
10 July 2024Craig-HallumMaintainsBuy—
3 Apr 2024Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INDV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INDV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Indivior Pharmaceuticals, Inc. returned +41.2% against +21.4% for the S&P 500, dividends included.

INDV vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26INDVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INDV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+14.4%
Analysts raising
2
Analysts cutting
0
Fundamentals

Indivior Pharmaceuticals, Inc. (INDV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.6×

Cheaper than 52% of US stocks

Price / sales
3.1×

Cheaper than 40% of US stocks

Price / book
−20.0×

Cheaper than 98% of US stocks

EV / EBITDA
7.7×

Cheaper than 46% of US stocks

Growth & margins
Revenue growth (YoY)
13.6%

Higher than 60% of US stocks

Earnings growth (YoY)
577.8%

Higher than 96% of US stocks

Gross margin
85.4%

Higher than 94% of US stocks

Operating margin
46.9%

Higher than 95% of US stocks

Net margin
26.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
−212.1%

Higher than 7% of US stocks

Return on assets
26.4%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Indivior Pharmaceuticals, Inc. (INDV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Indivior Pharmaceuticals, Inc. has a market value of $4.1B and an enterprise value of $4.4B.

  • Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 13.6% year on year.

  • Net income over the same four quarters: $355.0M, a 26.7% net margin.

  • Diluted earnings per share, trailing twelve months: $2.79.

  • Free cash flow in the twelve months to 30 June 2026: −$111.0M.

  • Indivior Pharmaceuticals, Inc. spent $302.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 118.0M.

  • Trailing P/E: 12.6×; forward P/E: 7.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Indivior Pharmaceuticals, Inc. employs 827 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

INDV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
INDVIndivior Pharmaceuticals, Inc.$4.1B
97
AMLXAmylyx Pharmaceuticals, Inc.$4.3B
59
RGCRegencell Bioscience Holdings Ltd.$3.1B
4
AMRXAmneal Pharmaceuticals, Inc.$5.7B
85
LQDALiquidia Corp.$6.0B
80
KNSAKiniksa Pharmaceuticals International Plc$6.1B
98
LNTHLantheus Holdings, Inc.$6.5B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Indivior Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INDV news & analysis

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 29 Aug 2026negative

Halper Sadeh LLC, an investor rights law firm, announced it is investigating whether Indivior Pharmaceuticals, Inc. is obtaining a fair price for its shareholders in its proposed merger with Supernus Pharmaceuticals, Inc. Upon closing, Indivior shareholders would own approximately 56.5% of the combined company.

Why it matters — A law firm investigation into the fairness of the merger terms signals potential concern among Indivior shareholders about the value of the proposed transaction.

3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)

Zacks Investment Research · 27 Aug 2026positive

Zacks Investment Research highlights Indivior Pharmaceuticals as a company with solid growth attributes that could help it outperform the market. The article identifies three reasons why growth investors should not overlook the company.

Why it matters — The piece signals that analysts see Indivior as having strong growth potential relative to the broader market.

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

Zacks Investment Research · 21 Aug 2026neutral

Indivior has proposed a merger with Supernus that, according to Zacks Investment Research, could broaden its central nervous system portfolio, cut costs, and reduce its reliance on the Sublocade product. However, the closing of the deal remains uncertain.

Why it matters — An INDV watcher would care because the merger could meaningfully diversify Indivior's growth engine and lower dependence on a single product, though completion is not yet assured.

Here's Why Indivior Pharmaceuticals Inc. (INDV) is a Strong Growth Stock

Zacks Investment Research · 13 Aug 2026positive

Zacks Investment Research highlighted Indivior Pharmaceuticals Inc. (INDV) as a strong growth stock using its Style Scores system, which helps investors identify top-rated stocks based on investing style.

Why it matters — The article positions INDV as a favorably rated stock according to Zacks' quantitative screening model, which could influence investor perception.

Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research · 11 Aug 2026positive

Zacks Investment Research published an analysis stating that Indivior Pharmaceuticals Inc. (INDV) has solid growth attributes that could help it outperform the market.

Why it matters — The article suggests INDV has favorable growth characteristics, which could influence investor perception of the company's potential.

FAQ

Frequently asked questions about INDV stock

What is the INDV stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Indivior Pharmaceuticals, Inc. have a median 12-month price target of $50, with estimates ranging from $43 to $53. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INDV stock a buy right now?

Of the 4 analysts covering Indivior Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Indivior Pharmaceuticals, Inc. 97 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INDV?

As at 2 Sept 2026, Indivior Pharmaceuticals, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will INDV stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +43.5% from the last close, and Ticker Nerd's factor model ranks Indivior Pharmaceuticals, Inc. 97 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INDV stock forecast for 2030?

No analyst covering Indivior Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INDV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $53 over the next 12 months.

How has INDV stock performed over the past year?

Indivior Pharmaceuticals, Inc. returned +41.2% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Indivior Pharmaceuticals, Inc. do?

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for opioid use disorder and related substance use disorders.

What is the latest news on INDV?

The most recent item we track (Business Wire, 29 Aug 2026): "INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders". Halper Sadeh LLC, an investor rights law firm, announced it is investigating whether Indivior Pharmaceuticals, Inc. is obtaining a fair price for its shareholders in its proposed merger with Supernus Pharmaceuticals, Inc. Upon closing, Indivior shareholders would own approximately 56.5% of the combined company.

Company

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for opioid use disorder and related substance use disorders. The company develops, manufactures, and markets buprenorphine-based prescription treatments designed to support recovery and long-term disease management in clinical settings. Its product portfolio includes branded therapies such as SUBLOCADE, SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX, which are used in addiction medicine and office-based treatment programs. Indivior serves patients, healthcare professionals, and treatment providers across the United States and other international markets, with a business centered on evidence-based care for chronic addiction conditions. The company also supports broader understanding of addiction medicine through clinical research, medical education, and treatment access initiatives. Headquartered in North Chesterfield, Virginia, Indivior plays a specialized role in the pharmaceutical market as a dedicated provider of addiction treatment therapies.

CEO Mr. Joseph J. Ciaffoni · 827 employees · United States · https://www.indivior.com